Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Abbott Laboratories Stock Research

ABT

95.79USD+0.06(+0.06%)Market Closed
Watchlist

Market Summary

USD95.79+0.06
Market Closed
0.06%

ABT Alerts

  • Big fall in Revenue (Y/Y)

ABT Stock Price

ABT RSI Chart

ABT Valuation

Market Cap

166.7B

Price/Earnings (Trailing)

32.3

Price/Sales (Trailing)

4.14

EV/EBITDA

19.55

Price/Free Cashflow

30.38

ABT Price/Sales (Trailing)

ABT Profitability

EBT Margin

16.85%

Return on Equity

15.68%

Return on Assets

7.87%

Free Cashflow Yield

3.29%

ABT Fundamentals

ABT Revenue

Revenue (TTM)

40.2B

Revenue Y/Y

-11.36%

Revenue Q/Q

2.37%

ABT Earnings

Earnings (TTM)

5.2B

Earnings Y/Y

-31.86%

Earnings Q/Q

4.32%

Price Action

52 Week Range

93.25115.83
(Low)(High)

Last 7 days

-1.8%

Last 30 days

-6.9%

Last 90 days

-10.7%

Trailing 12 Months

-0.6%

ABT Financial Health

Current Ratio

1.68

ABT Investor Care

Buy Backs (1Y)

0.77%

Diluted EPS (TTM)

2.93

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for ABT

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-09-13
Funck, Jr. Robert E.
gifted
-
-
-20,000
executive vice president
2023-09-13
Funck, Jr. Robert E.
gifted
-
-
10,000
executive vice president
2023-09-01
MCCOY JOHN A. JR.
acquired
-
-
531
vice president
2023-09-01
Boudreau Philip P
acquired
-
-
2,620
senior vice president
2023-08-08
Wainer Andrea F
acquired
192,000
38.4
5,000
executive vice president
2023-08-08
Wainer Andrea F
sold
-1,092,300
105
-10,400
executive vice president
2023-07-27
STARKS DANIEL J
sold
-5,688,190
113
-50,000
-
2023-07-01
Morrone Louis H.
sold (taxes)
-60,615
109
-556
executive vice president
2023-06-30
Morrone Louis H.
acquired
-
-
1,815
executive vice president
2023-06-16
Boudreau Philip P
sold
-848,000
106
-8,000
vice president

1–10 of 50

Which funds bought or sold ABT recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-10-02
PARK NATIONAL CORP /OH/
reduced
-2.12
-5,384,340
35,893,600
1.62%
2023-09-26
M Holdings Securities, Inc.
sold off
-100
-716,000
-
-%
2023-09-26
BROOKFIELD Corp /ON/
reduced
-48.38
-354,716
443,820
-%
2023-09-26
DecisionPoint Financial, LLC
reduced
-50.82
-2,906
3,271
-%
2023-09-21
Jefferies Group LLC
added
69.6
2,301,650
6,810,840
0.06%
2023-09-21
Baystate Wealth Management LLC
added
5.53
75,094
626,750
0.05%
2023-09-20
BARCLAYS PLC
added
145
217,115,000
349,401,000
0.22%
2023-09-19
BIRMINGHAM CAPITAL MANAGEMENT CO INC/AL
reduced
-6.23
24,845
2,625,200
1.10%
2023-09-18
CAPE ANN SAVINGS BANK
new
-
284,324
284,324
0.19%
2023-09-14
IMS Capital Management
unchanged
-
83,629
1,174,730
0.65%

1–10 of 44

Latest Funds Activity

Are funds buying ABT calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ABT
No. of Funds

Schedule 13G FIlings of Abbott Laboratories

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 09, 2023
vanguard group inc
8.92%
155,480,794
SC 13G/A
Feb 06, 2023
blackrock inc.
8.0%
139,526,216
SC 13G/A
Feb 09, 2022
vanguard group inc
8.43%
149,152,264
SC 13G/A
Feb 01, 2022
blackrock inc.
7.8%
137,155,602
SC 13G/A
Feb 16, 2021
capital research global investors
4.9%
86,394,199
SC 13G/A
Feb 10, 2021
vanguard group inc
8.31%
147,272,920
SC 13G/A
Jan 29, 2021
blackrock inc.
7.5%
133,426,810
SC 13G/A
Feb 14, 2020
capital research global investors
6.4%
113,689,293
SC 13G/A
Feb 12, 2020
vanguard group inc
8.58%
151,783,436
SC 13G/A
Feb 05, 2020
blackrock inc.
7.1%
124,728,602
SC 13G/A

Recent SEC filings of Abbott Laboratories

View All Filings
Date Filed Form Type Document
Sep 15, 2023
4
Insider Trading
Sep 06, 2023
3
Insider Trading
Sep 06, 2023
4
Insider Trading
Sep 06, 2023
4
Insider Trading
Sep 01, 2023
8-K/A
Current Report
Aug 10, 2023
4
Insider Trading
Aug 08, 2023
144
Notice of Insider Sale Intent
Aug 03, 2023
10-Q
Quarterly Report
Jul 28, 2023
4
Insider Trading
Jul 27, 2023
144
Notice of Insider Sale Intent

ABT Fair Value

Loading...

Peers (Alternatives to Abbott Laboratories)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
166.7B
40.2B
-6.92% -0.60%
32.3
4.14
-11.68% -39.67%
159.2B
30.4B
-19.52% -17.25%
25.04
5.25
-1.49% 0.14%
101.8B
31.6B
-5.31% -3.69%
28.08
3.23
1.57% -30.40%
101.2B
6.7B
-4.97% 57.37%
71.01
15.18
11.75% -0.66%
35.3B
3.5B
-15.71% 32.27%
44.63
10.05
6.21% 19.20%
MID-CAP
8.9B
937.8M
-9.65% 25.86%
306.13
9.51
16.30% 250.21%
3.8B
822.4M
-24.30% 26.41%
-165.38
4.6
56.01% -147.34%
-
-
-13.06% 1.72%
-
-
- -
SMALL-CAP
1.2B
254.9M
2.45% 31.18%
-62.25
4.89
-1.22% 15.74%
628.1M
240.7M
-7.40% -46.06%
-14.72
2.61
4.82% 85.44%
433.8M
130.6M
-14.72% 1.55%
-18.89
3.32
33.36% -414.87%
419.8M
76.9M
0.50% 67.22%
-10.54
5.46
22.01% -61.41%
119.8M
67.9M
-12.88% 59.77%
-13.57
1.76
21.30% -10.24%
40.3M
-
-30.99% -53.10%
-1.01
7.15
380.77% -31.71%

Abbott Laboratories News

MarketWatch
Abbott Laboratories stock underperforms Tuesday when compared to competitors despite daily gains.
MarketWatch,
5 hours ago
Investor's Business Daily
Morningstar

Returns for ABT

Cumulative Returns on ABT

13.0%


10-Year Cumulative Returns

14.1%


7-Year Cumulative Returns

7.3%


5-Year Cumulative Returns

-2.3%


3-Year Cumulative Returns

Risks for ABT

What is the probability of a big loss on ABT?

36.5%


Probability that Abbott Laboratories stock will be more than 20% underwater in next one year

5%


Probability that Abbott Laboratories stock will be more than 30% underwater in next one year.

0%


Probability that Abbott Laboratories stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does ABT drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Abbott Laboratories was unfortunately bought at previous high price.

Drawdowns

Financials for Abbott Laboratories

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue-3.1%40,22641,50543,65345,03045,54844,51443,07542,30840,23337,33834,60832,22131,44432,09531,90431,35530,93530,72330,57830,40229,575
Costs and Expenses-1.3%34,10134,54635,29135,59435,33635,28634,65033,82932,80530,63029,25127,90727,42727,54427,37227,04726,83026,94226,92827,26626,665
  S&GA Expenses-0.2%11,20611,22311,24811,32311,35911,32811,32410,84610,3819,9319,6969,5399,6779,8359,7659,7119,6489,6809,7449,8629,600
  R&D Expenses1.1%2,8762,8452,8882,9252,8152,7852,7422,6782,5862,4962,4202,3172,3332,3462,4402,4072,3852,3832,3002,3172,328
EBITDA-100.0%-8,83010,11811,16011,89710,95010,23510,2909,1936,9205,5144,3944,1064,7164,7474,4764,1273,8443,6993,3863,309
EBITDA Margin-100.0%-0.21*0.23*0.25*0.26*0.25*0.24*0.24*0.23*0.19*0.16*0.14*0.13*0.15*0.15*0.14*0.13*0.13*0.12*0.11*0.11*
Interest Expenses4.7%607580558535527529533538542542546574604638670692728770826886901
Earnings Before Taxes-10.2%6,2766,9928,3069,31310,0489,0448,2118,2727,2006,3784,9683,8203,5024,0784,0773,7843,3993,0742,8732,5002,408
EBT Margin-100.0%-0.17*0.19*0.21*0.22*0.20*0.19*0.20*0.18*0.17*0.14*0.12*0.11*0.13*0.13*0.12*0.11*0.10*0.09*0.08*0.08*
Net Income-11.1%5,1615,8046,9337,8898,5547,7257,0717,2446,3765,7244,4953,3823,1103,5793,6873,2922,8952,6222,368886926
Net Income Margin-100.0%-0.14*0.16*0.18*0.19*0.17*0.16*0.17*0.16*0.15*0.13*0.10*0.10*0.11*0.12*0.10*0.09*0.09*0.08*0.03*0.03*
Free Cashflow-100.0%-6,8237,8048,5418,4688,1528,6489,3148,6447,6095,7244,5874,5644,4764,4983,8144,0964,4504,9064,9034,816
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Assets-0.6%73,35473,79474,43872,80174,20274,00775,19673,79573,26972,78572,54869,04368,77666,77767,88768,53968,42767,61067,17371,63768,415
  Current Assets-3.6%23,50524,37725,22424,84524,95623,42924,23923,49222,62721,81720,44117,39017,22115,49815,66716,11915,19514,40914,63218,19614,122
    Cash Equivalents-14.5%7,8359,1619,8829,5948,9377,6759,7999,3028,6588,0546,8384,4804,7633,3773,8604,0913,1373,0223,8447,3693,065
  Inventory3.0%6,8716,6736,1735,7345,8995,6915,1575,2615,4395,3875,0125,1525,2024,5684,3164,3924,3524,0853,7963,7813,714
  Net PPE1.8%9,4499,2829,1628,6898,8188,9088,9598,8318,8168,8329,0298,6208,3437,9078,0387,8257,8257,6267,5637,4487,432
  Goodwill1.6%23,25822,90022,80022,28422,70023,20023,23123,29923,48523,38423,70023,30023,08222,90023,19523,00023,30023,20923,25423,41623,844
  Current Liabilities-1.2%14,35014,53015,48913,36512,39212,64713,10512,86712,61412,46211,90710,25710,95910,80810,86310,4919,0629,1139,01212,7768,951
  Short Term Borrowings--------197199199213208205204201204204201200211341
    LT Debt, Current0.0%2,2842,2852,2511,1175.004.007547547557567.006.001,2901,2641,2771,2548.008.007.004,063506
    LT Debt, Non Current-0.4%14,56214,61514,52215,29716,75517,08617,29617,44617,54717,48918,52718,34918,18416,80416,66117,63918,98218,84519,35919,28419,823
Shareholder's Equity0.4%37,17437,01036,68635,67536,49035,39935,80234,42233,80033,56232,78431,38630,57830,21831,08831,81731,68630,92530,52430,70530,577
  Retained Earnings1.4%36,35535,86835,25735,11534,48733,29531,52830,37629,05328,66927,62726,26625,66925,78625,84725,44025,04524,61324,56024,14424,080
Accumulated Depreciation1.4%11,47711,32311,05010,61710,64010,61310,40510,35110,2589,8659,7649,3529,0318,8008,7618,5188,5068,2798,1438,0727,877
Shares Outstanding-0.1%1,7401,742-1,7531,7541,762-1,7751,7791,777-1,7741,7731,769-1,7721,7691,763-1,7601,758
Minority Interest3.6%230222219209226230222216229226219209220209213202208204198193197
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations-13.9%7,4528,6599,58110,32210,2439,96110,53311,26410,6299,8237,9016,5196,4016,1396,1365,4855,7205,9046,3006,1755,997
  Share Based Compensation-1.5%651661685676667657640632618601546533527526519515504491477464456
Cashflow From Investing-51.5%-2,791-1,842-1,740-1,779-1,946-1,946-2,008-2,068-1,889-2,244-2,215-1,973-1,933-1,812-1,815-1,822-1,713-1,514-1,356-4,012-3,995
Cashflow From Financing-9.1%-5,699-5,223-7,636-8,065-7,899-8,350-5,494-4,395-4,933-3,011-2,779-4,177-2,775-3,882-4,289-6,880-3,896-5,078-10,391-5,727-8,584
  Dividend Payments1.8%3,4293,3673,3093,2843,2593,2343,2023,0452,8832,7222,5602,4872,4172,3432,2702,1972,1222,0481,9741,9431,912
  Buy Backs20.8%2,4492,0283,7954,0843,8654,3312,2991,486909442403738737737718326328327238145150

ABT Income Statement

2023-06-30
Condensed Consolidated Statement of Earnings (Unaudited) - USD ($)
shares in Thousands, $ in Millions
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Income Statement [Abstract]    
Net sales$ 9,978$ 11,257$ 19,725$ 23,152
Cost of products sold, excluding amortization of intangible assets4,4834,9338,8149,920
Amortization of intangible assets4985079891,019
Research and development7156841,3691,381
Selling, general and administrative2,7402,7575,5025,544
Total operating cost and expenses8,4368,88116,67417,864
Operating earnings1,5422,3763,0515,288
Interest expense159132312263
Interest (income)(98)(26)(199)(40)
Net foreign exchange (gain) loss21027(3)
Other (income) expense, net(176)(82)(287)(160)
Earnings before taxes1,6362,3523,1985,228
Taxes on earnings261334505763
Net Earnings$ 1,375$ 2,018$ 2,693$ 4,465
Basic Earnings Per Common Share (in dollars per share)$ 0.79$ 1.15$ 1.54$ 2.53
Diluted Earnings Per Common Share (in dollars per share)$ 0.78$ 1.14$ 1.53$ 2.51
Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share (in shares)1,740,3591,753,8651,741,0511,757,858
Dilutive Common Stock Options (in shares)9,88911,5989,93312,115
Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options (in shares)1,750,2481,765,4631,750,9841,769,973
Outstanding Common Stock Options Having No Dilutive Effect (in shares)5,4745,4195,4742,655

ABT Balance Sheet

2023-06-30
Condensed Consolidated Balance Sheet (Unaudited) - USD ($)
$ in Millions
Jun. 30, 2023
Dec. 31, 2022
Current Assets:  
Cash and cash equivalents$ 7,835$ 9,882
Short-term investments320288
Trade receivables, less allowances of $485 in 2023 and $500 in 20226,1726,218
Inventories:  
Finished products4,0043,805
Work in process845680
Materials2,0221,688
Total inventories6,8716,173
Prepaid expenses and other receivables2,3072,663
Total Current Assets23,50525,224
Investments799766
Property and equipment, at cost20,92620,212
Less: accumulated depreciation and amortization11,47711,050
Net property and equipment9,4499,162
Intangible assets, net of amortization9,83410,454
Goodwill23,25822,799
Deferred income taxes and other assets6,5096,033
Total Assets73,35474,438
Current Liabilities:  
Trade accounts payable4,2114,607
Salaries, wages and commissions1,3621,556
Other accrued liabilities5,3345,845
Dividends payable886887
Income taxes payable273343
Current portion of long-term debt2,2842,251
Total Current Liabilities14,35015,489
Long-term debt14,56214,522
Post-employment obligations, deferred income taxes and other long-term liabilities7,0387,522
Commitments and Contingencies
Shareholders’ Investment:  
Preferred shares, one dollar par value Authorized — 1,000,000 shares, none issued00
Common shares, without par value Authorized — 2,400,000,000 shares Issued at stated capital amount — Shares: 2023: 1,987,181,491; 2022: 1,986,519,27824,61224,709
Common shares held in treasury, at cost — Shares: 2023: 251,823,511; 2022: 248,724,257(15,722)(15,229)
Earnings employed in the business36,35535,257
Accumulated other comprehensive income (loss)(8,071)(8,051)
Total Abbott Shareholders’ Investment37,17436,686
Noncontrolling Interests in Subsidiaries230219
Total Shareholders’ Investment37,40436,905
Total Liabilities and Shareholders' Investment$ 73,354$ 74,438
Robert B. Ford
65535
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.